This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

XOMA's CEO Presents At The Eighth Annual Lazard Capital Markets Healthcare Conference - Conference Call Transcript

Stocks in this article: XOMA


Lazard Capital Markets Healthcare Conference 2011

November 15, 2011 1 AM ET


John Varian – Interim CEO

Paul Rubin – VP, Clinical Development and Chief Medical Officer



[Starts Abruptly] introduce John Varian, who will be presenting to us today about his company XOMA.

John Varian

Thanks Colleen, and thank you to Lazard for having us present here giving us the opportunity to talk about XOMA and some of the new changes that are going on there. I joined the company at the end of August as the interim CEO. I've been involved with XOMA for the last nearly almost 3 years as a board member, and during those 3 years our focus has been on really one thing. XOMA is a company that over the years has had terrific science but there is a belief among the board and I think many others that XOMA has not really benefited as much from its own discoveries as it should have and so our focus has been on changing that making sure we are in a position to benefit from our own discoveries.

We’ll be making forward-looking statements of course today. So if you look at the assets that we have at XOMA the primary asset the thing that most people are focused on is XOMA 052 and it has just received its official name which is gevokizumab. So gevokizumab, it will be 052 we’ll be saying it that way today. Gevokizumab targets IL-1 beta, which is a validated anti-inflammatory target. We will be talking primarily today about an announcement which we made last week, which is a combination of really two things that we are implementing to build more value around gevokizumab.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs